BioNTech’s 2Q Revenue Soars

BioNTech

2Q Revenues: €5.3 billion (revenues were €41.7 million 2Q20)

2Q Earnings: €2.8 billion (loss of €88.3 million 2Q20)

Comments: Revenue growth due to rapid increases in the supply of COVID-19 vaccine worldwide. More than one billion doses of BNT162b2 have been supplied to more than 100 countries or territories worldwide as of July 21, 2021. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. In the quarter, BioNTech’s commercial revenues included an estimated €3.9 billion of gross profit share and €168.6 million of sales milestones. During the six months ended June 30, 2021, BioNTech’s commercial revenues included an estimated amount of €5.4 billion.

BioNTech and Pfizer believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently tested variants, including Delta. The companies are developing and will test an updated version of the COVID-19 vaccine that targets the full spike protein of the Delta variant. The companies anticipate the clinical study to begin in August 2021, subject to regulatory approvals.

In July 2021, BioNTech and Pfizer began a Phase 3 clinical trial to evaluate the safety, tolerability and efficacy of a 30µg booster dose of BNT162b2 versus placebo in approximately 10,000 participants aged 16 years and older who have previously received two doses of BNT162b2 at least six months prior to randomization.

BioNTech and Pfizer expect BNT162b2 annual manufacturing capacity to reach three billion doses by the end of 2021 and expect to have capacity to manufacture up to four billion doses in 2022.

BioNTech’s oncology pipeline currently includes 15 product candidates in 18 ongoing trials.

Influenza Vaccine Program, BNT161 is expected to start a Phase 1 clinical trial in 3Q21. The clinical trial will evaluate modified RNA influenza vaccine candidates based on the proven BNT162b2 COVID-19 vaccine platform. BNT161 is partnered with Pfizer.